Prelude Therapeutics IncorporatedPRLDNASDAQ
Loading
Other Income/Expenses (Net) Over TimeContracting
Percentile Rank57
3Y CAGR-14.5%
5Y CAGR+22.5%
Studio
Year-over-Year Change

Net other income and expenses outside core operations

3Y CAGR
-14.5%/yr
vs +128.9%/yr prior
5Y CAGR
+22.5%/yr
Recent deceleration
Acceleration
-143.4pp
Decelerating
Percentile
P57
Within normal range
vs 5Y Ago
2.8x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$5.07M-59.6%
2024$12.54M+20.1%
2023$10.44M+28.9%
2022$8.10M+297.0%
2021$2.04M+11.3%
2020$1.83M+240.3%
2019$539000.00+82.7%
2018$295000.00-